A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study To Assess Safety And Efficacy Of Elad In Subjects With Alcohol-Induced Liver Decompensation (AILD)

Trial Profile

A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study To Assess Safety And Efficacy Of Elad In Subjects With Alcohol-Induced Liver Decompensation (AILD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Extracorporeal hepatocyte-based therapy (Primary)
  • Indications Alcoholic hepatitis; Liver failure
  • Focus Therapeutic Use
  • Sponsors Vital Therapies
  • Most Recent Events

    • 22 Mar 2018 According to a Vital Therapies media release, the company today announced that the trial has reached its enrollment target of 150 subjects.
    • 13 Mar 2018 Updated baseline data of the first 147 subjects, presented in a Vital Therapies media release.
    • 13 Mar 2018 According to a Vital Therapies media release, enrollment for this study nears completion with 147 subjects enrolled as of 12 Mar 2018.The company expects to complete enrollment this month and is on track for release of topline results in third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top